Spiro compound
By preparing and using specific compounds to inhibit WRN helicase, the problem of difficulty in effectively treating cancers related to DNA mismatch repair function in the prior art is solved, effective inhibition of MSI-H cells is achieved, and a new treatment is provided means.
Patent Information
- Application Number
- CN202411321261.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-20
AI Technical Summary
The prior art is difficult to effectively treat cancers related to high instability of microsatellites caused by the lack of DNA mismatch repair function, especially colorectal cancer, gastric cancer, endometrial cancer and ovarian cancer. The inhibition of the decoylation function of WRN protein is considered to be is a potential therapeutic strategy, but lacks effective compounds or methods.
Provided is a compound or a pharmaceutically acceptable salt thereof for the preparation of an inhibitor of WRN helicase for the treatment of the above-mentioned cancers, by synthesizing a compound of a specific structure and combining with a carrier, to form a pharmaceutical composition to inhibit the function of WRN .
This compound or its salt can effectively inhibit the helicase activity of WRN, resulting in the breakdown of TA repeat sequences in MSI-H cells, thereby inhibiting the growth and division of cancer cells, providing a new treatment for microsatellites with high instability and Methods for repairing cancers related to DNA mismatch.
Smart Images

Figure CN119039303A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a spiro compound, application thereof and a pharmaceutical composition containing the spiro compound. Background Art
[0002] During the progression of cancer, loss of DNA mismatch repair function often occurs, such as in 10%-30% of colorectal cancer, endometrial cancer, ovarian cancer and gastric cancer. Due to the loss of DNA mismatch repair function, the mutation burden of cancer cells becomes higher, and deletions or insertions often occur in the repetitive sequence regions of DNA. This phenomenon is called microsatellite instability. Although progress has been made in the treatment of microsatellite high instability (MSI-H) cancer, and pembrolizumab (PD-1 antibody) as a first-line treatment shows a longer survival progression period than chemotherapy for patients with advanced colorectal cancer with microsatellite high instability / DNA mismatch repair function loss (MSI-H / dMMR), pembrolizumab has been approved for the first-line treatment of MSI-H / dMMR cancer, but there is still a demand for colorectal cancer and other MSI-H indications in clinical practice.
[0003] Through large-scale functional genomics screening of multiple cell lines, including Novartis' analysis of 398 cell lines from the Cancer Cell Line Encyclopedia (CCLE) cell bank (McDonald E R et al., Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell 170 (3): 577-592 (2017)), it was found that WRN (Werner syndrome protein) is essential for the survival of cell lines with microsatellite high instability (MSI-H) due to loss of DNA mismatch function (Behan, FM et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511-516 (2019); Chan, EM et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568,551-556(2019); Kategaya,L.,Perumal,SK,Hager,JH&Belmont,LDWerner syndrome helicase is required for the survival ofcancer cells with microsatellite instability.iScience 13,488-497(2019); Lieb,S.etal.Werner syndrome helicase is a selective vulnerability ofmicrosatellite instability-high tumor cells.Elife 8,e43333(2019)). WRN and MSI-H have a synthetic lethal relationship. In cancer cells with DNA mismatch repair function deficiency, the loss of WRN inhibits cell proliferation, activates multiple DNA damage biomarkers, and induces cell division arrest and apoptosis. However, for cancer cells with intact DNA mismatch repair function, the loss of WRN does not lead to such results.These findings indicate that WRN provides the DNA repair and maintenance functions that MSI-H cancer cells rely on for survival. Recently, the mechanism by which MSI-H cells rely on WRN has been studied: the two-nucleotide TA repeat sequence is unstable only in MSI-H cells, and can be amplified on a large scale, thereby forming an atypical DNA secondary structure that requires WRN to unwind (Van Wietmarschen, N. et al. Repeat expansions confer WRN dependency in microsatellite-unstable cancers. Nature 586, 292-298, 200.). In the absence of WRN (or the unwinding function of WRN is inhibited), the amplified TA repeat sequence in MSI-H cells will be cut by nucleases, resulting in chromosome breakage. Therefore, for cancer cells with DNA mismatch function loss, inhibiting the helicase function of WRN is an attractive therapeutic strategy.
[0004] New management and treatment approaches are still needed for cancer, especially for cancers with microsatellite instability-high (MSI-H) or deficient DNA mismatch repair (dMMR), including colorectal, gastric, endometrial, or ovarian cancers. Summary of the invention
[0005] The present invention provides a compound of the following formula (I) or a pharmaceutically acceptable salt thereof:
[0006]
[0007] Among them, R 1 H or C 1-3 Alkyl; R 2 OH or -NH-(CO)-C 1-3 alkyl.
[0008] In a more preferred embodiment, R 1 is H or methyl; R 2 OH or -NH-(CO)-CH 3 .
[0009] The compound or pharmaceutically acceptable salt thereof described in the present invention may be any of the following compounds:
[0010]
[0011] The present invention also provides the use of the compound shown above or a pharmaceutically acceptable salt thereof in the preparation of a WRN inhibitor, including the use in the treatment of colorectal cancer, gastric cancer, endometrial cancer or ovarian cancer.
[0012] The present invention also provides a pharmaceutical composition, which comprises the compound shown above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0013] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. DETAILED DESCRIPTION
[0014] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0015] Example 1 EVO32781
[0016]
[0017] Step 1:
[0018] Sodium 3-carboxybenzenesulfonate (326.87 mg, 1.46 mmol), N,N-dimethylformamide (6 mL), HATU (655.24 mg, 1.72 mmol), N,N-diisopropylethylamine (513.97 mg, 3.98 mmol, 692.68 μL), 2-BOC-2,7-diaza-spiro[4.4]nonane (300.00 mg, 1.33 mmol) were added to the reaction bottle, and the reaction solution was stirred at room temperature for 3 hours under argon protection. LC-MS showed that the product was generated and the raw material reacted completely. The reaction solution was quenched by adding water (1 mL). The residue was directly purified by reverse phase column (water (containing 0.1% formic acid) / acetonitrile system) and concentrated to obtain yellow foamy solid EVO32781-A1 (500.00 mg, yield 91.89%). LCMS (ESI) m / z = 409.1 [MH] - .
[0019] Step 2:
[0020] EVO32781-A1 (500.00 mg, 1.22 mmol), dichloromethane (6 mL), trifluoroacetic acid (2.98 g, 26.14 mmol, 2 mL) were added to the reaction flask, and the reaction solution was stirred at room temperature for 2 hours. LC-MS showed that the product was generated and the raw materials reacted completely. The reaction solution was concentrated under reduced pressure, and dichloromethane (20 mL) was added to the residue and concentrated again. This operation was repeated three times to obtain a yellow oil EVO32781-A2 (400.00 mg,). The product was used directly in the next step without further separation. LCMS (ESI) m / z = 409.1 [MH] - .
[0021] Step 3:
[0022] EVO32781-A2 (400.00 mg, crude product), dichloromethane (5 mL), N,N-diisopropylethylamine (832.83 mg, 6.44 mmol, 1.12 mL) were added to the reaction flask, and a dichloromethane (1 mL) solution of acryloyl chloride (128.31 mg, 1.42 mmol) was added dropwise under an ice-water bath, and the reaction solution was stirred at room temperature for 2 hours. LC-MS showed that the product was generated and the raw materials reacted completely. The reaction solution was directly purified by preparative HPLC to obtain a light yellow solid EVO32781 (5.00 mg, yield 1.06%). LCMS (ESI) m / z = 363.3 [MH] - . 1 HNMR (400 MHz, DMSO-d 6 )δ7.79-7.62(m,2H),7.54-7.35(m,2H),6.65-6.44(m,1H),6.19-6.03(m,1H) ,5.71-5.57(m,1H),3.71-3.50(m,4H),3.42-3.24(m,4H),2.11-1.75(m,4H).
[0023] Example 2 EVO32853
[0024]
[0025] Step 1:
[0026] At room temperature, EVO32845-A0 (2.5 g, 10.91 mmol), benzyl mercaptan (1.63 g, 13.10 mmol), Pd 2 (dba) 3 (699mg, 0.76mmol), XantPhos (947mg, 1.64mmol), DIPEA (4.23g, 32.74mmol) and 1,4-dioxane (25mL). The reaction system was replaced with argon three times, heated to 100°C and stirred overnight. After the reaction was completed, it was cooled to room temperature, filtered, and the filter cake was washed with DCM. The filtrate was concentrated to obtain a crude product, which was purified by medium pressure normal phase column (PE / EA=0-6%) to obtain EVO32845-A1 (2.5g) as a light yellow oil. LCMS (ESI) m / z=273.2[M+H] + .
[0027] Step 2:
[0028] EVO32845-A1 (1.5 g, 5.51 mmol) was dissolved in CH 3 CN / H2 O / HOAc (20 mL, 200 / 5 / 2.5), and then dichlorohydantoin (1.63 g, 8.26 mmol) was added. The reaction system was stirred at 0°C for 1 hour. The reaction system was concentrated to obtain crude product EVO32845-A2 (1.7 g) as a light yellow solid.
[0029] LCMS (ESI) m / z = 229.2 [MH] - .
[0030] Step 3:
[0031] At 0°C, EVO32845-A2 (1.7 g, 6.84 mmol) was dissolved in THF (20 mL), and then ammonia water (10 mL) was added. The reaction system was stirred at 0°C for 1-2 hours. The reaction system was diluted with water and extracted twice with ethyl acetate. The organic phases were combined and concentrated to obtain a crude product, which was slurried with PE / EA (5 / 1), filtered, and the filter cake was dried to obtain EVO32845-A3 (1 g) as a white solid. LCMS (ESI) m / z = 230.2
[0032] [M+H] + .
[0033] Step 4:
[0034] At 0°C, EVO32845-A3 (1 g, 4.36 mmol) and TEA (1.32 g, 13.09 mmol) were dissolved in THF (15 mL), and acetyl chloride (514 mg, 6.54 mmol) was added. The reaction system was stirred at room temperature overnight. After the reaction was completed, the crude product was directly concentrated and purified by medium pressure normal phase column (DCM / 10% MeOH = 0-15%) to obtain EVO32845-A4 (0.8 g) as a light yellow solid.
[0035] LCMS (ESI) m / z = 270.3 [MH] - .
[0036] Step 5:
[0037] EVO32845-A4 (150 mg, 0.55 mmol) was dissolved in THF (6 mL) and H 2 O (2mL), and then add LiOH.H2O (70mg, 1.66mmol). The reaction system was stirred at room temperature overnight. The reaction system was adjusted to pH 3-5 with HCl (1M) and concentrated to obtain crude EVO32845-A5 (160mg) as a light yellow solid. LCMS (ESI) m / z = 256.1 [MH] - .
[0038] Step 6:
[0039] At room temperature, EVO32845-A5 (80 mg, 0.31 mmol) was dissolved in DMF (3 mL), and HATU (177 mg, 0.47 mmol) was added. The reaction system was stirred at room temperature for 5-10 minutes, and then a DMF (1 mL) solution of EVO32853-A0 (70 mg, 0.31 mmol) and TEA (94 mg, 0.93 mmol) were added. The reaction system was stirred at room temperature for 1 hour. The reaction system was directly purified by medium pressure reverse phase column (0.1% HCOOH in H 2 O / CH 3 CN=5%-65%) and then freeze-dried to obtain EVO32853-A1 (100 mg) as a white solid. LCMS (ESI) m / z=464.4[MH] - .
[0040] Step 7:
[0041] At room temperature, EVO32853-A1 (100 mg, 0.21 mmol) was dissolved in DCM (5 mL), and TFA (2 mL) was added. The reaction system was stirred at room temperature for 1 hour. The reaction system was concentrated to obtain the crude product EVO32853-A2 (100 mg) as a light yellow oil. LCMS (ESI) m / z = 366.3 [M+H] + .
[0042] Step 8:
[0043] At 0°C, EVO32853-A2 (100 mg, 0.27 mmol) and TEA (111 mg, 1.09 mmol) were dissolved in THF (5 mL), and acryloyl chloride (37 mg, 0.41 mmol) was added. The reaction system was stirred at room temperature for 3-4 hours. After the reaction system was concentrated, it was prepared by prep-HPLC (acidic preparation) to obtain an impure crude product, which was then purified by prep-TLC (DCM / MeOH=15 / 1) and freeze-dried to obtain EVO32853 (14 mg, yield: 12.20%) as a white solid. LCMS (ESI) m / z=420.2 [M+H] + .HPLC: 97.6%. 1 H NMR (400 MHz, DMSO-d 6)δ7.70-7.61(m,2H),7.45-7.38(m,1H),6.62-6.48(m,1H),6.17-6.05(m,1H),5.69-5.6 0(m,1H),3.68-3.37(m,8H),2.36(d,J=4.0Hz,3H),2.04-1.78(m,4H),1.70-1.68(m,3H).
[0044] Biological Effect Examples
[0045] Protein expression and purification of WRN truncation
[0046] Construction of expression vector:
[0047] 1. Synthesize the cDNA sequence encoding WRN (N517-Q1093) (Genscript Biotech
[0048] Corporation) with an 8xHis tag-Strep-TEV cleavage site at the N-terminus.
[0049] into pFastBac1 vector (YouBio, catalog number), with insertion sites at BamHI and EcoRI,
[0050] to pFastBac1-8His-Strep-TEV-WRN(N517-Q1093) recombinant plasmid;
[0051] 2. Take 50 μL DH10Bac competent cells (biomed, #BC112-01) and slowly melt them on ice, add 1 μL pFastBac1-8His-Strep-TEV-WRN (N517-Q1093) recombinant plasmid, incubate on ice for 30 minutes, then incubate in 42°C water bath for 45 seconds, and incubate on ice for 2 minutes;
[0052] 3. Add 450 μL SOC medium (2% Tryptone (OXOID, #LP0042), 0.5% Yeast Extract (OXIOD, #LP0021), 0.58% NaCl (Hushi, #10019360), 0.019% KCl (Hushi, 1002792168398), 0.203% MgCl 2 6H 2 O(Hushi, 10012828), 0.246%MgSO 4 7H 2O (Hushi, 10013016), 0.36% Glucose (Biodee, #DE0149-500g)), placed in a horizontal shaker at 220 rpm and 37°C for 4 h;
[0053] 4. Dilute the cell suspension 10-fold with SOC medium, and then take 50uL to coat agarose plate (take 1% Tryptone, 0.5% Yeast Extract, 1% NaCl, 1.5% Agar (BioFroxx,
[0054] #8211GR500), 50μg / mL Kanamycin (Solarbio, #K8020-5g), 7μg / mL Gentamycin (Solarbio, G8170-1g), 10μg / mL Tetracycline (Solarbio, #T8180-5g), 40μg / mL X-gal (Solarbio, #8050-1g) and 40μg / ml IPTG (lnalco, #1758-1400), 37°C, protected from light for 48h;
[0055] 5. Pick two monoclonal colonies and place them in 5 mL SOC medium respectively, and culture them at 37°C and 250 rpm overnight;
[0056] Extraction of recombinant Bacmid:
[0057] 1. Take 1.5 mL of colony culture medium into an EP tube (Axygen, #MCT-200-CS) and centrifuge at 13300 rpm for 1 minute;
[0058] 2. Remove the supernatant and extract the recombinant Bacmid using a plasmid extraction kit (Qiagen #DP103-03). Refer to the kit instructions for the experimental steps. Transfer the supernatant after centrifugation to a new tube, add 750 μL isopropanol (Greagent, #G75885B), mix gently several times, and place on ice for 10 minutes;
[0062] 3.13, centrifuge at 300 rpm for 15 minutes;
[0063] 4. Remove the supernatant, add 500 μL 70% ethanol (Greagent, Cat. No. 1101143), flip the EP tube 8 times, wash the precipitate, and centrifuge at 13,300 rpm for 5 minutes;
[0064] 5. Remove the supernatant and add 500 μL of autoclaved 70% ethanol in a sterile environment of a clean bench;
[0065] 6. Repeat steps 8 and 9;
[0066] 7. Remove excess supernatant as much as possible and centrifuge at 13,300 rpm for 2 minutes;
[0067] 8. Air-dry the precipitate for 5 minutes and dissolve it in 40 μL of autoclaved TE buffer;
[0068] 9. Determine the concentration of recombinant Bacmid using Nanodrop;
[0069] Insect cell transfection:
[0070] 1. Dilute Sf9 cells (Gibco, #11496015) to 1×10 6 cells / mL, take 3mL into a 25mL culture flask;
[0072] 2. Take 15 μg recombinant Bacmid, add 100 μL Grace's Insect Medium (Gibco, #11605094), then add 7 μL X-treme transfection reagent (Roche #6366236001), and incubate at room temperature for 15-20 minutes
[0075] 3. The incubation product was transferred to a culture flask containing Sf9 cell solution and cultured at 27°C and 100 rpm for 4 days;
[0076] Collect P0 virus:
[0077] 4. Observe the cell status 4 days after transfection and prepare to collect the virus;
[0078] 5. First add serum (final concentration 2%, Sijiqing #11011-8611), centrifuge at 3200 rpm for 5 minutes at 4°C;
[0079] 6. Collect the supernatant and store at 4°C, which is recorded as P0 virus;
[0080] P1 virus preparation:
[0081] 7. Take 1 mL of P0 virus and add 50 mL of Sf9 cell culture medium (cell density 1.5-1.8×10 6 cells / mL), cultured at 27°C and 100 rpm for 3 days;
[0083] 8. After 3 days of culture, detect the cell status and prepare to collect the cells;
[0084] 9. Add serum (final concentration 2%) and centrifuge at 3500 rpm for 5 minutes at 4°C;
[0085] 10. Collect the supernatant and store at 4°C, which is recorded as P1 virus;
[0086] P2 virus preparation:
[0087] 11. Take 4 mL of P1 virus and add it to 200 mL of Sf9 cell culture medium (cell density 1.5-1.8×10 6 cells / mL), cultured at 27°C and 100 rpm for 3 days;
[0089] 12. After 3 days of culture, detect the cell status and prepare to collect the cells;
[0090] 13. Add serum (final concentration 2%) and centrifuge at 3500 rpm for 5 minutes at 4°C;
[0091] 14. Collect the supernatant and store it at 4°C, which is recorded as P2 virus.
[0092] Protein expression and purification:
[0093] 15.6 bottles of 800mL Sf9 cell culture medium (2×10 6 cells / mL), 12.8 mL of P2 virus was added to each of the 100 cells / mL cells and cultured at 27°C and 100 rpm for 48 h;
[0094] Centrifuge at 8000 rpm for 10 min at 16.4°C to collect cells;
[0095] 17. Resuspend the cells in 800 mL of cell lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 1 mM PMSF, 5 mM MgCl2) and add one tablet of cOmplete™ protein inhibitor (Roche #11697498001);
[0097] 18. High-pressure cell disruption (Nanjing Natong Electromechanical Manufacturing, model NT-H3, working pressure 650 bar), repeated disruption 4 times, followed by centrifugation at 4°C 16000 rpm for 60 minutes, and the supernatant was collected for affinity chromatography:
[0099] 1) Strep- XT affinity column (5 mL, IBA lifesciences #2-5027-001), eluted with a buffer of 50 mM HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP, 1 mM PMSF, 75 mM Biotin;
[0102] 2) Add 6His-GST-Thrombin-TEV protease to the eluted product and digest it overnight at 4°C;
[0103] 3) The digested product was passed through HiTrap Heparin HP (5 mL, GE Healthcare #17-0406-01) for ion exchange;
[0104] 4) Remove residual protease by GST column;
[0105] 5) Purification was performed by size exclusion chromatography using HiLoad 16 / 600 Superdex 200 pg (GE Healthcare #28-9893-35) at a flow rate of 1 mL / min;
[0106] 19. SDS-PAGE was used to detect protein purity. The protein purity should be greater than 99%. The protein was frozen at -80°C for subsequent enzyme activity testing.
[0107] Inhibition assay of compounds on ATPase activity of WRN truncated forms
[0108] ADP-Glo TM The kinase kit (Promega #V9101) is a chemiluminescent ADP detection method with the advantages of strong versatility, good uniformity and high-throughput screening. It can be used to detect the activity of ADP-generating enzymes (such as ATPase). The test is carried out in two steps: first, after the kinase reaction, ADP-Glo TM The reagent terminates the kinase reaction and consumes the remaining ATP; then the kinase detection reagent is added to convert ADP into ATP, and the newly synthesized ATP is measured by the luciferase / luciferin reaction, and the chemiluminescent signal is detected by the photometer. The light signal is positively correlated with the content of ADP, so the inhibition of WRNATPase activity by compounds of different concentrations can be measured, thereby fitting the concentration-effect curve and calculating the IC50 of the compound. The specific steps are as follows:
[0109] The buffer used in this experiment was 25 mM HEPES (Gibco #15630-080), 5 mM NaCl (Sigma #59222C-100ML), 0.01% F-127 (Sigma #P2443), 1 mM MgCl 2 (Sigma#M1028-100ML), 1mM TCEP (Sigma#646547).
[0110] 1. Dissolve the compound in DMSO to prepare a 10 mM stock solution, and dilute the compound to be tested in a 3-fold gradient, with a total of 8 dilution points. Take 3uL of the compound solution and add it to a No. 1 384-well plate (PerkinElmer
[0111] #6008280). Add 3uL 5% DMSO to the minimum inhibition control well (High Control) and the no enzyme control well (Low Control) respectively;
[0112] 2. Add 6uL of 5nM WRN truncation solution to each well and incubate with the compound for 10 minutes at room temperature.
[0113] 3. Add 6uL of ATP and DNA duplex fork solution (2.5mM ATP, 25nM
[0114] DNA), prepared into 15uL reaction system, reacted at room temperature for 60 minutes;
[0115] 4. Take 5uL of the reaction system into each well and add 5uL of ADP Glo reagent stop solution (ADP-Glo TM Kinase kit) in No. 2 384-well plate, incubate at room temperature for 50 minutes, and terminate the reaction;
[0116] 5. Take 5uL ADP (ADP-Glo TM Kinase kit) was added with 5uL ADP Glo reagent (ADP-Glo TM Kinase kit) wells (standard control wells);
[0117] 6. Add 10uL Kinase Detection Reagent (ADP-Glo TM Kinase kit) and incubated at room temperature for 40 minutes. The optical signal value was read using SpectraMaxi3x;
[0118] 7. Data analysis: Compound well inhibition rate (Inhibition%) = (avg High Control-Cpd well) / (avg High Control-Low Control)*100%. GraphPad Prism 9.0 software was used to draw the concentration effect curve and calculate IC using the four-parameter fitting equation. 50 value.
[0119] Detection of the inhibition of DNA unwinding activity of WRN truncations by compounds
[0120] Experimental principle: After annealing, two incompletely paired single-stranded DNA fragments with a quencher and a fluorescent group can form a DNA duplex fork structure. WRN can unwind the DNA duplex fork into single-stranded DNA, thereby detecting the level of single-stranded DNA through fluorescent signals and evaluating the helicase activity of WRN. The specific experimental steps are as follows:
[0121] The buffer used in this experiment is consistent with the buffer formula of the ATPase activity experiment.
[0122] 1. Synthesize single-stranded DNA fragment (quenched single-stranded DNA of SEQ ID NO: 1:
[0123] TTTTTTTTTTTTTTTTTTCGTACCCGATGTGTTCGTTC, fluorescent single-stranded DNA of SEQ ID NO: 2: GAACGAACACATCGGGTACGTTTTTTTT, synthesized by Shanghai Sangon Biotechnology Co., Ltd., purified by HPLC), enzyme-free water (Invitrogen
[0124] #10977015) Dissolve the primer to 100uM;
[0125] 2. Dilute the single-stranded DNA fragments to 20uM with 500mM NaCl solution (final NaCl concentration 50mM), and make up the volume with enzyme-free water. Take equal amounts of single-stranded DNA fragments and mix them (10uM), put them into a PCR instrument (BIORAD#C1000 Touch), and set the program to: 95℃ for 5 minutes, 25℃ for 1 minute (Ramp: 0.1℃ / s), 4℃ for 30 minutes, anneal the single-stranded DNA, and obtain a DNA duplexfork;
[0130] 3. Take 20uL 30nM fluorescent single-stranded DNA fragment and 20uL 30nM DNA duplex fork into 384-well plate (Corning#4514) respectively, and detect the fluorescence signal with microplate reader: excitation wavelength 520nm emission wavelength 590nm. Calculate the annealing efficiency according to the corresponding fluorescence signals: (DNA duplex fork / single-stranded DNA)×100%, annealing efficiency must be>90%;
[0132] 4. The compound was dissolved in DMSO to prepare a 10 mM stock solution, and the compound to be tested was diluted 3-fold in a gradient, with a total of 10 dilution points (7.5× compound detection concentration, 7.5% DMSO);
[0133] 5. Take 2uL of compound solution and add it to a 384-well plate. Add 2uL of 7.5% DMSO to the minimum inhibition control well (High Control) and the no enzyme control well (Low Control) respectively;
[0134] 6. Add 5uL of 6nM WRN truncation solution to each well, centrifuge at 1000rmp for 1 minute, and incubate at room temperature for 30 minutes;
[0135] 7. Add 8uL of a mixture of DNA duplex fork and ATP (18.75nM DNA, 5.63mM ATP) to each well, centrifuge at 1000rmp for 1 minute, and react at room temperature for 20 minutes;
[0136] 8. Add 4uL 1.625% SDS solution (Sigma #75746-250G) to each well to terminate the reaction;
[0137] 9. Use a fluorescence microplate reader (MD SpectraMax i3x) to read the fluorescence signal intensity with an excitation wavelength of 520 nm and an emission wavelength of 590 nm;
[0139] 10. Data analysis: Compound well inhibition rate (Inhibition%) = (avg High Control-Cpdwell) / (avg High Control-Low Control)*100%. GraphPad Prism 9.0 software was used to draw the concentration effect curve and calculate IC using the four-parameter fitting equation. 50 The results are as follows: Where A represents IC 50 ≤100nM; B means 100nM<IC 50 ≤1000nM; C means 1000nM<IC 50 ≤10000nM; “-” means not tested.
Claims
1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: in, R1 is H or C 1-3 Alkyl; R2 is OH or -NH-(CO)-C 1-3 alkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is H or methyl.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is OH or -NH-(CO)-CH3.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is any of the following compounds:
5. A pharmaceutical composition, characterized in that It comprises the compound according to any one of claims 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
6. Use of the compound or pharmaceutically acceptable salt or pharmaceutical composition according to any one of claims 1 to 5 in the preparation of a WRN inhibitor.
7. The use according to claim 6 is for treating colorectal cancer, gastric cancer, endometrial cancer or ovarian cancer.
Citation Information
Patent Citations
Covalent inhibitors of KRAS G12C
CN105189456A
1-azaspirocycle compound, and preparation method and applications thereof
CN108456208A
Spiro compound
CN111285887A
Selective her2 inhibitors
CN117645616A
Covalent molecular glue stabilizers and platform
WO2023129332A1
Cited By
Pharmaceutical combinations and uses thereof
WO2025215527A2
